NCT03821077View on ClinicalTrials.gov

"Study to Evaluate the Efficacy and Safety of Allergovac Poliplus in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma"

CompletedOBSERVATIONAL

Enrollment

122

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

September 13, 2021

Study Completion Date

September 13, 2021

Conditions

Rhinitis, AllergicRhinoconjunctivitis

Interventions

BIOLOGICAL

Allergen Immunotherapy (AIT)

Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation

Trial Locations (10)

Unknown

Centre Assistencial Baix Llobregat, Cornellà de Llobregat

Hospital de Igualada, Igualada

GAME Centre Medic, Sant Boi de Llobregat

Fundación Hospital Calahorra, Calahorra

CAR SAn Millán, Logroño

Centro médico Promosalud, Logroño

Allercen, Barcelona

Centre Medic Catalonia, Barcelona

Hospital QuironSalud Barcelona, Barcelona

Hospital Sanitas CIMA, Barcelona

All Listed Sponsors

lead

Roxall Medicina España S.A

INDUSTRY

NCT03821077 - "Study to Evaluate the Efficacy and Safety of Allergovac Poliplus in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma" | Biotech Hunter | Biotech Hunter